Topics

AbbVie Submits sNDA to the FDA for Imbruvica in Combination with Rituximab for Previously Untreated Younger Adults with CLL

10:13 EST 8 Nov 2019 | Speciality Pharma Journal

NORTH CHICAGO, Ill., Nov. 8, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA® (ibrutinib) in combination with rituximab for the first-line treatment of younger patients (70 years old or younger) with chronic lymphocytic leukemia (CLL) …

Original Article: AbbVie Submits sNDA to the FDA for Imbruvica in Combination with Rituximab for Previously Untreated Younger Adults with CLL

NEXT ARTICLE

More From BioPortfolio on "AbbVie Submits sNDA to the FDA for Imbruvica in Combination with Rituximab for Previously Untreated Younger Adults with CLL"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...